PreveCeutical Medical is an early stage biotech with ample risk in a nascent development pipeline. Nonetheless, the Company has made progress with its development projects, demonstrating the ability of the scientific team to execute on the R&D agenda. Highest priority on the Company’s agenda is a non-opioid pain treatment compound based on cannabinoids and administered […]
Author: Crystal Equity Research
Updated Coverage – Westwater Resources (WWR)
There has been a mix of current events for energy materials developer Westwater Resources. The Company released a business plan for its recently acquired natural flake graphite asset in Alabama. The plan brings into a single focus a series of tactical decisions Westwater management has made since the deal closed to bring battery grade graphite […]
Updated Coverage – Westwater Resources (WWR)
We have updated coverage of energy materials developer Westwater Resources (WWR) following report of financial resulting in the quarter ending March 2018, and other developments in the Company’s asset portfolio. In April 2018, Westwater completed the previously announced acquisition of Alabama Graphite. Management confirmed plans to develop what could be the first domestic source of […]
Updated Coverage – PreveCeutical Medical (PRVCF)
Our coverage of PreveCeutical Medical (PRVCF) is updated with comments on recent progress with the Company’s portfolio of research and development projects focused on preventative therapeutics. The Company has several major achievements in recent months, moving the R&D pipeline closer to goals. In March 2018, the Company’s research and development partner UniQuest Pty. Ltd. began […]
New Coverage – Westwater Resources (WWR)
We initiated coverage of Westwater Resources with a Speculative Buy rating and a one-year target price of $1.50 based on an estimated intrinsic value of $5.00 per share and tempered by recent trading patterns. Westwater is a building portfolio of energy materials assets that creates a triple threat of uranium, lithium and now graphite. The […]